Catherine Curran1, Neetha Byrappa, Andrew McBride. 1. Pendine Community Mental Health Trust, 124-126 Cowbridge Road West, Ely, Cardiff CF5 5BT, Wales, UK. Cath.Curran@CardiffandVale.wales.nhs.uk
Abstract
BACKGROUND: Psychosis associated with stimulant use is an increasing problem, but there is little research evidence about the nature of the problem and its management. AIMS: To critically review the literature on stimulant psychosis and sensitisation. METHOD: Systematic review of studies that have investigated stimulant use and psychosis in humans. The main outcome measures were increases in psychosis with stimulant use, and differences between stimulant users and non-users. RESULTS: Fifty-four studies met the inclusion criteria. Experimental studies show that a single dose of a stimulant drug can produce a brief increase in psychosis ratings (a "response") in 50-70% of participants with schizophrenia and pre-existing acute psychotic symptoms, unaffected by the presence of antipsychotic medication. Those with schizophrenia who do not have acute psychotic symptoms respond, but less frequently (30%). There has been little research into the longer-term effects of use. CONCLUSIONS: Compliance with antipsychotic medication by someone with schizophrenia will not prevent a relapse or worsening of psychotic symptoms if stimulants are used. Low-dose antipsychotic treatment may be beneficial in stimulant users, to prevent sensitisation.
BACKGROUND:Psychosis associated with stimulant use is an increasing problem, but there is little research evidence about the nature of the problem and its management. AIMS: To critically review the literature on stimulant psychosis and sensitisation. METHOD: Systematic review of studies that have investigated stimulant use and psychosis in humans. The main outcome measures were increases in psychosis with stimulant use, and differences between stimulant users and non-users. RESULTS: Fifty-four studies met the inclusion criteria. Experimental studies show that a single dose of a stimulant drug can produce a brief increase in psychosis ratings (a "response") in 50-70% of participants with schizophrenia and pre-existing acute psychotic symptoms, unaffected by the presence of antipsychotic medication. Those with schizophrenia who do not have acute psychotic symptoms respond, but less frequently (30%). There has been little research into the longer-term effects of use. CONCLUSIONS: Compliance with antipsychotic medication by someone with schizophrenia will not prevent a relapse or worsening of psychotic symptoms if stimulants are used. Low-dose antipsychotic treatment may be beneficial in stimulant users, to prevent sensitisation.
Authors: Philip Seeman; David Weinshenker; Remi Quirion; Lalit K Srivastava; Sanjeev K Bhardwaj; David K Grandy; Richard T Premont; Tatyana D Sotnikova; Patricia Boksa; Mufida El-Ghundi; Brian F O'dowd; Susan R George; Melissa L Perreault; Pekka T Männistö; Siobhan Robinson; Richard D Palmiter; Teresa Tallerico Journal: Proc Natl Acad Sci U S A Date: 2005-02-16 Impact factor: 11.205
Authors: Clinton E Canal; Drake Morgan; Daniel Felsing; Krishnakanth Kondabolu; Neil E Rowland; Kimberly L Robertson; Rajeev Sakhuja; Raymond G Booth Journal: J Pharmacol Exp Ther Date: 2014-02-21 Impact factor: 4.030
Authors: Jan-Peter van Wieringen; Jan Booij; Vladimir Shalgunov; Philip Elsinga; Martin C Michel Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2012-12-09 Impact factor: 3.000